Abcam, ab258984, Human NACA (NACA1) knockout HEK-293T cell lysate

Size: 1Kit
NACA KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 2.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 2.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-NACA, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
NACA1 also known as Nascent Polypeptide-Associated Complex Alpha-1 is a vital protein in cells with a molecular mass of around 21 kDa. It plays a big role as a transcription factor and coordinates the synthesis and proper folding of nascent polypeptides. This protein shows high expression in various tissues including muscle brain and liver. As a multifunctional player NACA1 assists in safeguarding polypeptides emerging during protein synthesis ensuring they achieve correct conformation and function.
Biological function summary
NACA1 modulates transcriptional activity interacting with particular sequences in DNA to affect gene expression. It forms a part of the nascent polypeptide-associated complex (NAC) that helps modulate developing polypeptides and ribosome-associated processes. By working in tandem with other proteins NACA1 not only contributes to protein folding but also aids in the regulation of stress responses. This highlights its importance in ensuring proteins function correctly under various cellular conditions.
Pathways
NACA1 engages in the regulation of protein homeostasis and gene expression pathways. It is involved in the unfolded protein response (UPR) and interacts with other ribosome-associated proteins. NACA1 plays a role in stress-response pathways ensuring proteins are correctly processed and folded under stress conditions. It may interact with other proteins like Hsp70 and ribosomal proteins to enhance protein quality control ensuring normal cellular function.
NACA1's dysregulation relates to conditions such as myopathies and cancer. Altered expression or function can disrupt normal stress response pathways resulting in muscle weakness or tumor progression. Researchers have noted its potential link with BRCA1-associated breast cancer and impacts seen in muscular diseases suggesting it may influence disease progression through its interaction with genes and proteins central to these disorders. Understanding NACA1’s role can support the development of new therapeutic strategies for these conditions.